Is Summit Therapeutics profitable?

Summit Therapeutics is not currently profitable: it reported a net loss of $1.2B over the trailing twelve months, a -271685.0% net margin.

What is Summit Therapeutics's earnings per share?

Summit Therapeutics's diluted EPS over the trailing twelve months is $-1.59.

Where does Summit Therapeutics's income statement data come from?

Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Summit Therapeutics SMMT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Research and development	$537.67M+257%	$150.78M+154%	$59.47M+14.4%	$52M-39.1%
General and administrative	$556.75M+825%	$60.21M+106%	$29.26M+9.4%	$26.74M+13.3%
Total operating expenses	$1.09B+384%	$226M-62.9%	$609.65M+599%	$87.21M-20.0%
Other income (expense), net	$14.84M+11.0%	$13.37M+19.5%	$11.18M—	——
Net income	-$1.08B-388%	-$221.32M+64.0%	-$614.93M-681%	-$78.78M+11.1%
Diluted earnings per share	-$1.44-350%	-$0.32+78.5%	-$1.49-263%	-$0.41+39.7%
Basic earnings per share	-$1.44-350%	-$0.32+78.5%	-$1.49-263%	-$0.41+39.7%
Weighted-average shares, diluted	3B+4.1%	2.9B+19.3%	2.4B+251%	682.4M+68.3%
Weighted-average shares, basic	3B+4.1%	2.9B+19.3%	2.4B+251%	682.4M+68.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$1.08B-389%	-$221.05M+64.1%	-$615.48M-684%	-$78.48M+9.8%
Depreciation	$146K+64.0%	$89K-55.1%	$198K-43.3%	$349K+5.8%
Effect of currency exchange rate changes on cash, cash equivalents, and restricted cash	——	——	——	——
Accounts payable	——	——	——	-$4.13M-141%
Accrued liabilities	$12.93M+8.8%	$11.88M—	——	$4.82M-12.3%
Accrued compensation and employee benefits	——	$6.56M—	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	$617.53M+52.5%	$404.84M+368%	$86.59M-86.0%	$620.24M+696%
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$174.31M—	——	——	——
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	-$322.93M-127%	-$142.11M-85.1%	-$76.76M—	——
Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax	-$327K-304%	$160K+194%	-$171K-156%	$304K—
Other Comprehensive Income Loss Available For Sale Securities Adjustment Before Reclassification Adjustments Net Of Tax	$72K—	——	$36K—	$0—
Payments to Acquire Property, Plant, and Equipment	$657K+373%	$139K+8.6%	$128K—	——
Payments to Acquire Short-Term Investments	$484.99M-28.7%	$680.03M+112%	$321.02M—	$0—
Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options	$5.65M+107%	$2.74M+195%	$929K+133%	$399K—
Stock-based compensation	$732.42M+1,337%	$50.98M+261%	$14.11M+18.1%	$11.95M-6.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Summit Therapeutics profitable?: Summit Therapeutics is not currently profitable: it reported a net loss of $1.2B over the trailing twelve months, a -271685.0% net margin.
What is Summit Therapeutics's earnings per share?: Summit Therapeutics's diluted EPS over the trailing twelve months is $-1.59.
Where does Summit Therapeutics's income statement data come from?: Every line is extracted from Summit Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.